ClinicalTrials.gov
ClinicalTrials.gov Menu

Post Marketing Surveillance Study of Cuprimine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01374282
Recruitment Status : No longer available
First Posted : June 15, 2011
Last Update Posted : October 22, 2015
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Brief Summary:
Cuprimine (penicillamine) was made available in the Philippines by the Sponsor under a Compassionate Special Permit issued by the Bureau of Food and Drugs. Physicians were able to request the drug for their patients from the Sponsor. A Clinical Study Report form was completed for each purchase of Cuprimine.

Condition or disease Intervention/treatment
Scleroderma Drug: Cuprimine (penicillamine)

Study Type : Expanded Access
Official Title: Post Marketing Surveillance Study of Cuprimine (MK-0172-001)

Resource links provided by the National Library of Medicine

U.S. FDA Resources


Intervention Details:
    Drug: Cuprimine (penicillamine)
    Dosage determined by the physician based on indication for treatment

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

- None

Exclusion Criteria:

- None


No Contacts or Locations Provided

Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT01374282     History of Changes
Other Study ID Numbers: 0172-001
First Posted: June 15, 2011    Key Record Dates
Last Update Posted: October 22, 2015
Last Verified: October 2015

Additional relevant MeSH terms:
Penicillamine
Antidotes
Protective Agents
Physiological Effects of Drugs
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action
Antirheumatic Agents